Mexico Nuclear Medicine Market Size & Outlook, 2023-2030
Mexico nuclear medicine market, 2018-2030 (US$M)
Related Markets
Mexico nuclear medicine market highlights
- The Mexico nuclear medicine market generated a revenue of USD 109.5 million in 2023 and is expected to reach USD 218.4 million by 2030.
- The Mexico market is expected to grow at a CAGR of 10.4% from 2024 to 2030.
- In terms of segment, diagnostics was the largest revenue generating product in 2023.
- Therapeutics is the most lucrative product segment registering the fastest growth during the forecast period.
Nuclear medicine market data book summary
| Market revenue in 2023 | USD 109.5 million |
| Market revenue in 2030 | USD 218.4 million |
| Growth rate | 10.4% (CAGR from 2023 to 2030) |
| Largest segment | Diagnostics |
| Fastest growing segment | Therapeutics |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Diagnostics, Therapeutics |
| Key market players worldwide | GE HealthCare Technologies Inc Common Stock, Jubilant Pharmova, Nordion, Bracco, Iren SpA, Abliva AB, Lantheus Holdings Inc, Eckert & Ziegler Bebig SA, Mallinckrodt PLC Ordinary Shares - New, Cardinal Health Inc |
Other key industry trends
- In terms of revenue, Mexico accounted for 1.1% of the global nuclear medicine market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Latin America, Brazil nuclear medicine market is projected to lead the regional market in terms of revenue in 2030.
- Mexico is the fastest growing regional market in Latin America and is projected to reach USD 218.4 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Nuclear Medicine Market Scope
Nuclear Medicine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Mexico nuclear medicine market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to nuclear medicine market will help companies and investors design strategic landscapes.
Diagnostics was the largest segment with a revenue share of 77.08% in 2023. Horizon Databook has segmented the Mexico nuclear medicine market based on diagnostics, therapeutics covering the revenue growth of each sub-segment from 2018 to 2030.
Increasing collaborations and partnerships among players in the nuclear medicine market are expected to fuel market growth. In January 2019, Telix Pharmaceuticals entered into an agreement with Mexico’s Instituto Nacional de Investi gaciones Nucleares (ININ) for 99m-Tc-iPSMA. This is a clinical-stage radiopharmaceutical product used in the imaging of prostate cancer.
According to IARC, in 2020, ~195,000 new cancer cases were diagnosed in Mexico, leading to nearly 90,200 deaths. These numbers are likely to increase by 44% and 51%, respectively, by 2030. The growing incidence of cardiovascular diseases is expected to boost market growth.
For instance, as stated by the International Journal of Public Health in a global burden disease study of cardiovascular diseases in Mexico, between 1990-2017, ischemic heart disease accounted for almost two-thirds of all cardiovas cularrelated deaths. In the management of ischemic heart disease, PET based cardiac nuclear imaging plays a crucial role.
Reasons to subscribe to Mexico nuclear medicine market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Mexico nuclear medicine market databook
-
Our clientele includes a mix of nuclear medicine market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Mexico nuclear medicine market , including forecasts for subscribers. This country databook contains high-level insights into Mexico nuclear medicine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Mexico nuclear medicine market size, by product, 2018-2030 (US$M)
Mexico Nuclear Medicine Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
